Join to View Full Profile
170 Manning DriveCB# 7305Chapel Hill, NC 27599
Phone+1 919-966-1996
Dr. Peters is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Since the beginning of my medical education, I have been fascinated by the fact that the human immune system would allow cancerous cells to persist and even take over the human body. I have sought out every opportunity during my clinical years to learn more about cancer and the people affected. From start to finish, I have been extremely underwhelmed by traditional, cytotoxic chemotherapy. While often necessary and sometimes helpful, it is a blunt tool that I hope will be used more sparingly in the future as our treatments evolve to a more individualized approach. Even in the relatively short time that I've been in training, there have been incredible advances in cancer treatment with new, more targeted, and individualized treatments. I am interested in exploring (1) cellular therapies, (2) novel biologics, and (3) immunomodulatory drugs to unlock or reinvigorate host immune responses to treat blood cancers (leukemia)
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2022
Johns Hopkins UniversityInternship, Internal Medicine, 2019 - 2022
University of South Carolina School of MedicineClass of 2019
Certifications & Licensure
NC State Medical License 2023 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 1 citationsRefined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters
Blood. 2024-12-26 - 1 citationsTranslocation (11;14) is a common cytogenetic abnormality in clonal plasma cells in monoclonal immunoglobulin deposition disease.Divaya Bhutani, Yusha Liu, Rajshekhar Chakraborty, Jai Radhakrishnan, Suzanne Lentzsch
British Journal of Haematology. 2024-11-01 - 7 citationsBuilding safety into CAR-T therapy.Daniel T Peters, Barbara Savoldo, Natalie S Grover
Human Vaccines & Immunotherapeutics. 2023-12-15
Journal Articles
- Building safety into CAR-T therapyDaniel T. Peters, Barbara Savoldo, Natalie S. Grover, Human Vaccines and Immunotherapeutics, 11/15/2023
Grant Support
- UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training ProgramUniversity of North Carolina2023–2025
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
